Deal Watch: NASH In The Hot Seat
Executive Summary
Regeneron stayed busy during the past two weeks, collaborating and making an equity commitment to CRISPR gene-editing biotech Intellia and signing an immuno-oncology deal with MedImmune. Allergan bounced off the termination of its merger with Pfizer by partnering with Heptares in neurological disease.
You may also be interested in...
Synta's Merger With Madrigal Creates New Entrant In NASH Race
Moving past its late-stage clinical failure with ganetespib, Synta will combine with Madrigal to develop a Phase II-ready compound for NASH and hypercholesterolemia.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.